Limited Offer
Progress in Medicinal Chemistry
- 1st Edition, Volume 63 - November 1, 2024
- Editors: Jonathan Bentley, Tilly Bingham
- Language: English
- Hardback ISBN:9 7 8 - 0 - 4 4 3 - 2 9 7 8 0 - 9
- eBook ISBN:9 7 8 - 0 - 4 4 3 - 2 9 7 8 1 - 6
Progress in Medicinal Chemistry, Volume 63 highlights new advances in the field, with this new volume presenting interesting chapters written by an international board of author… Read more
Purchase options
Institutional subscription on ScienceDirect
Request a sales quote- Provides extended, timely reviews of topics in medicinal chemistry
- Contains targets and technologies relevant to the discovery of tomorrow’s drugs
- Presents analyses of successful drug discovery programs
Praful Chovatia, Angelo Sanzone, Gert-Jan Hofman, Bernardo Pezzati, Ruth Dooley, Iuni Trist and Gilles Ouvry
2. Recent Advances in the Medicinal Chemistry of Heterobifunctional Derivatives for Protein Homeostasis.
Allan Jordan
3. A Decade of Antimalarial Drug Discovery: New Targets, Tools and Molecules
Dale Taylor
- No. of pages: 260
- Language: English
- Edition: 1
- Volume: 63
- Published: November 1, 2024
- Imprint: Elsevier
- Hardback ISBN: 9780443297809
- eBook ISBN: 9780443297816
JB
Jonathan Bentley
TB
Tilly Bingham
Tilly (Matilda) Bingham is a drug discoverer with over 20 years’ experience of working in the pharmaceutical R&D sector in ‘large pharma’ (Organon, Schering-Plough, MSD), Biotech (Redx Pharma), CRO (Concept Life Sciences) and is currently Executive in Residence at Cumulus Oncology. Tilly’s early career was spent working as a medicinal chemist in CNS therapeutic areas where her research focussed on design strategies for getting small molecule therapeutics across the blood brain barrier for targets including the GPCRs OX2R, V1R and CGRP. Then, as Head of Research and Operations at Redx Pharma she oversaw the discovery and development of oncology and fibrosis clinical candidates, including the clinical candidate porcupine inhibitors RXC004 (oncology), RXC006 (AZD5055, fibrosis), Pan RAF inhibitor (JZP815) and FDA approved BTK inhibitor Pirtobrutinib. As VP Science and Chief Scientific Officer at the UK CRO Concept Life Sciences she oversaw multiple research programmes and the development of new research capability across the group. In her current role as Executive in Residence at Cumulus Oncology Tilly is employing her significant expertise in pre-clinical drug discovery to accelerate oncology innovation to key value inflection points.